The future of obesity therapeutics is being written now – be a part of it! Visit the full agenda and speakers here: ...

Novo Nordisk A/S (NYSE:NVO) develops, manufactures, and distributes pharmaceutical products focused on diabetes, obesity, ...

Novo Nordisk (NVO) stock was down on Tuesday, despite a lack of news from the pharmaceutical company. Instead, investors can ...

A competitor reported a successful late-stage clinical trial of a drug that could be very competitive with Wegovy.

Elli Lily said on Tuesday that its daily weight loss pill helped patients lose weight, specifically those with obesity and ...

New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes ...

Eli Lilly's GLP-1 pill, orforglipron, shows promising trial results for weight loss and type 2 diabetes. Global regulatory ...

Orforglipron will be submitted to global regulatory authorities for the treatment of obesity or for weight loss by the end of ...

The 36-mg dose brought the greatest weight loss, 10.5%, while the 12-mg dose group shed 7.8% of their body weight on average.

Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly's Zepbound and Novo Nordisk's Wegovy.

Novo Nordisk said on Monday it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...

A growing number of patients claim popular weight loss and diabetes drugs like Ozempic can cause a rare but very serious side ...